Overview

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Status:
Recruiting
Trial end date:
2022-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Benralizumab